TFCP2L1 and cancer: Here, we demonstrated upregulation of the CDK1‐TFCP2L1 pathway in BCs and showed that it was associated with aggressive clinicopathological features, such as high tumor grade and stage, as well as frequent LVI, muscularis propria invasion, distant metastasis, and cancer‐specific death.